



BLOOM BURTON & CO.
HEALTHCARE INVESTOR CONFERENCE
APRIL 20-21, 2021



Bloom Burton & Co. exists to accelerate returns in the healthcare sector for both companies and investors. There is no greater illustration of the power of our platform than this conference, which has grown into Canada's flagship healthcare investment and networking event over the past ten years.

WELCOME

Bloom Burton & Co. exists to accelerate returns in the healthcare sector for companies and investors alike. We offer investment banking services such as capital raising, M&A advisory, equity research, sales and trading and monetization planning, as well as scientific and business advisory services. We have expanded our direct investment capabilities by offering several healthcare dedicated funds to investors. We have also matured our company incubation activity, the portfolio of which now includes five companies are presenting at this very conference. The 2021 Bloom Burton & Co. Healthcare Investor Conference is our 9th edition in the past 10 years and is one of the most important events in the calendar for our sector.

Last November, we held our fourth Bloom Burton Award Gala – even if it necessitated being held virtually. The celebration of dramatic and significant contributions to the Canadian and global healthcare industry in a specific year never goes out of style and it has become a pre-eminent event to showcase those very special achievements. We will be holding our next Bloom Burton Award Gala late this year and the three finalists for this year’s award will be announced this week!

We are humbled to serve as a major catalyst for our industry and we are grateful for and proud of our team, who work tirelessly to serve our clients. We strive to produce exceptional deliverables and outcomes and we are here for you as you learn about the great presenting companies and meet new investors as you plan for the success of the healthcare sector in Canada.

Attendance for this year’s event is very strong again and thank you for having joined us for this event.

Have a wonderful conference!

Brian, Jolyon and the entire team

CONTENT

- 06.** **Agenda**
- 10.** **Keynote Speaker**
- 12.** **Panelists**
- 22.** **Company Profiles**
- 90.** **Sponsors**
- 98.** **Logistics**

ABOUT

Bloom Burton & Co. Healthcare Investor Conference

April 20, 2021 - April 21, 2021

The Bloom Burton & Co. Healthcare Investor Conference attracts Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies. Investors have the opportunity to obtain corporate updates from presenting companies, and participate in our 1-on-1 meeting system with company management.



AGENDA

Tuesday, April 20, 2021

Private Public

All times are Eastern Time (ET)

9:00AM	Opening Remarks:	Brian Bloom Co-founder, Chairman and Chief Executive Officer
9:30AM	TSX Opens (Virtual)	

	Biotechnology	Medical Technology	Specialty Pharma
9:30AM	● Repare Therapeutic (NASDAQ:RPTX)	<input type="radio"/> Synaptive Medical	● Knight Therapeutics (TSX:GUD)
10:00AM	● Medicenna Therapeutics (TSX:MDNA, NASDAQ:MDNA)	<input type="radio"/> Intellijoint Surgical	<input type="radio"/> Searchlight Pharma
10:30AM	● Fusion Pharmaceuticals (NASDAQ:FUSN)	<input type="radio"/> AceAge	<input type="radio"/> Grey Wolf Animal Health
11:00AM	● ESSA Pharma (NASDAQ:EPIX)	<input type="radio"/> Precision Biomonitoring	● Medexus Pharmaceuticals (TSXV:MDP)
11:30AM	● Zymeworks (NYSE:ZYME)	<input type="radio"/> Kardium	● Mimi's Rock (TSXV:MIMI)

DAY 1

Tuesday, April 20, 2021

12:30PM Keynote Speaker: **Scott Gottlieb, M.D.**
23rd Commissioner of the U.S. FDA

	Biotechnology	Services / Digital Health	Tools
1:30PM	● AbCellera (NASDAQ:ABCL)	● WELL Health Technologies (TSX:WELL)	○ Virica Biotech
2:00PM	● Bellus Health (TSX:BLU, NASDAQ:BLU)	● Viemed (TSX:VMD, NASDAQ:VMD)	○ Nicoya Life Sciences
2:30PM	● Aurinia Pharmaceuticals (TSX:AUP, NASDAQ:AUPH)	● MindBeacon (TSX:MBCN)	○ ARTMS
3:00PM	● Xenon Pharmaceuticals (NASDAQ:XENE)	● CloudMD Software & Services (TSXV:DOC)	○ FERRO International
3:30PM	● Chinook Therapeutics (NASDAQ:KDNY)	● Skylight Health Group (TSXV:SHG)	○ Domain Therapeutics
4:00PM	● IMV (TSX:IMV, NASDAQ:IMV)	● CareRx (TSX:CRRX)	● Eupraxia Pharmaceuticals (TSX:EPRX)

AGENDA

Wednesday, April 21, 2021

○ Private ● Public

All times are Eastern Time (ET)

8:30AM Panel Discussion: Investing in R&D Stage Healthcare Companies

Mike Dybbs, PhD
Partner, Samsara BioCapital

Ellen Hukkelhoven, PhD
Managing Director, Perceptive Advisors

Rohan Nirody, MBA
Portfolio Manager, Viking Global Investors

	Biotechnology	Services / Digital Health	Tools
9:30AM	● Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY)	● Crescita Therapeutics (TSX:CTX)	○ Triumvira Immunologics
10:00AM	● Appili Therapeutics (TSX:APLI)	● Miravo Healthcare (TSX:MRV)	○ Notch Therapeutics
10:30AM	● Theratechnologies (TSX:TH, NASDAQ:THTX)	● HLS Therapeutics (TSX:HLS)	○ Fibrocor Therapeutics
11:00AM	● Antibe Therapeutics (TSX:ATE)	● BioSyent (TSXV:RX)	○ Zucara Therapeutics
11:30AM	○ Dot Health	● Aequus Pharmaceuticals (TSXV:AQS)	○ Satellos Bioscience

DAY 2

Wednesday, April 21, 2021

12:30PM Panel Discussion: Investing in Commercial Stage Healthcare Companies

Garheng Kong, MD, PhD, MBA
Managing Partner, HealthQuest Capital

Allyson Rinderle, MBA
Principal, Private Equity, KKR

M. Craig Shepherd, LLB, MBA
Senior Managing Director, Blackstone

	Biotechnology	Services / Digital Health	Tools
1:30PM	○ AlayaCare	● Profound Medical (TSX:PRN, NASDAQ:PROF)	● Field Trip Health (CSE:FTRP)
2:00PM	● Dialogue Health Technologies (TSX:CARE)	● Titan Medical (TSX:TMD, NASDAQ:TMDI)	● Cybin (NEO:CYBN)
2:30PM	○ League	● Hamilton Thorne (TSXV:HTL)	● Microbix Biosystems (TSX:MBX)
3:00PM	● Think Research (TSXV:THNK)	○ Canary Medical	● Avivagen (TSXV:VIV)
3:30PM	● Newtopia (TSXV:NEWU)	● OpSens (TSX:OPS)	○ Medicago
4:00PM	● NeuPath Health (TSXV:NPTH)	● Perimeter Medical Imaging (TSXV:PINK)	○ Inversago

KEYNOTE SPEAKER

Tuesday, April 20, 2021 | 12:30PM - 1:30PM

Scott Gottlieb, M.D.

23rd Commissioner of the U.S. FDA

Scott Gottlieb, M.D.

23rd Commissioner of the U.S. FDA

Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S Food and Drug Administration. Dr. Gottlieb's work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.



PANELISTS

Our panelists are recognized industry leaders who have made worthwhile contributions to the healthcare sector globally.

Wednesday, April 21, 2021 | 8:30 AM - 9:30 AM

Investing in R&D Stage Healthcare Companies

Wednesday, April 21, 2021 | 12:30 PM - 1:30 PM

Investing in Commercial Stage Healthcare Companies

Wednesday, April 21, 2021 | 8:30 AM - 9:30 AM

Investing in R&D Stage Healthcare Companies

Mike Dybbs, PhD

Partner, Samsara BioCapital

Ellen Hukkelhoven, PhD

Managing Director, Perceptive Advisors

Rohan Nirody, MBA

Portfolio Manager, Viking Global Investors

Wednesday, April 21, 2021 | 12:30 PM - 1:30 PM

Investing in Commercial Stage Healthcare Companies

Garheng Kong, MD, PhD, MBA

Managing Partner, HealthQuest Capital

Allyson Rinderle, MBA

Principal, Private Equity, KKR

M. Craig Shepherd, LLB, MBA

Senior Managing Director, Blackstone

PANEL

Wednesday, April 21, 2021 | 8:30 AM - 9:30 AM

Investing in R&D Stage Healthcare Companies

PANEL

Investing in R&D Stage Healthcare Companies

Mike Dybbs, PhD

Partner, Samsara BioCapital

Mike Dybbs is a Partner at Samsara BioCapital, where he invests across all stages of the life science sector from seed stage to public equities. He currently serves on the board of a number of Samsara portfolio companies, including: Enara Bio, IONpath, Levo Therapeutics, Nkarta Therapeutics and Sutro (STRO).

Prior to Samsara, Mike was a Partner at New Leaf Venture Partners. Mike has served on the boards of Versartis (VSAR), Dimension Therapeutics (DMTX), Advanced Cell Diagnostics (acquired by Bio-Techne) and Principia. Before joining New Leaf, Mike was a Principal at the Boston Consulting Group, where he was a core member of their health care practice.

Mike received an A.B. in biochemical sciences from Harvard and a PhD in molecular biology from UC Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. His research was published in peer-reviewed journals, including Nature, Science, and Neuron.



PANEL

Investing in R&D Stage Healthcare Companies

Ellen Hukkelhoven, PhD

Managing Director, Perceptive Advisors

Ellen Hukkelhoven joined Perceptive in 2013 as a Senior Biotechnology Analyst. At Perceptive, she focuses on public and private development stage therapeutic companies. Ellen serves on the boards of MeiraGTx, Freenome, Kindbody, AavantiBio and Partner Therapeutics. She is also a member of the Board of Overseers of the Columbia Mailman School of Public Health. Prior to Perceptive, Ellen received her PhD in Cancer Biology from Memorial Sloan Kettering Cancer Center. During her tenure at MSKCC, she founded and built the life sciences division of InSITE, a top graduate fellowship program that helps early stage companies with their most pressing needs. Ellen graduated magna cum laude from Princeton University with degrees in molecular biology and finance.



PANEL

Investing in R&D Stage Healthcare Companies

Rohan Nirody, MBA

Portfolio Manager, Viking Global Investors

Mr. Nirody is responsible for identifying and researching ideas for private investments, primarily in the healthcare sector. Mr. Nirody is based in Viking's San Francisco office. Prior to this, he was an Investment Analyst on Viking's public investment team responsible for identifying and researching investment ideas in the healthcare sector. From 2005 to 2007, Mr. Nirody was an Associate at Elevation Partners, a media-focused private equity firm, where he was responsible for the identification, evaluation and execution of private equity investments. Prior to joining Elevation Partners, Mr. Nirody spent two years as a Private Equity Analyst at the Blackstone Group. Mr. Nirody received an MBA from Harvard Business School and a B.S. in economics and B.A. in international studies, summa cum laude, from the University of Pennsylvania.



PANEL

Wednesday, April 21, 2021 | 12:30 PM - 1:30 PM

Investing in Commercial Stage Healthcare Companies

PANEL

Investing in Commercial Stage Healthcare Companies

Garheng Kong, MD, PhD, MBA

Managing Partner, HealthQuest Capital

Garheng founded HealthQuest Capital in 2012 to improve people's lives through improving healthcare on a significant scale. His vision was to build a best-in-class team of the highest talent and integrity to work with outstanding entrepreneurs to transform healthcare through high growth companies while generating outsized risk adjusted returns for investors.

A physician, scientist, and engineer by training, Garheng has over two decades of experience investing in innovative healthcare companies with a long list of successes (25 IPO/M&A exits). He has represented HealthQuest on the boards of Ajax I, Ajax II, Ajax III, Alcresta, Avedro, Avizia, BardyDx, Castle Biosciences, CleanSlate, Etairos, ENT Specialty Partners, Everlywell, HealthChannels, Magnolia Medical, Perspectum, Pulmonx, Spirox, TigerConnect, Trice Medical, Venus Concept, and CareMetx/VirMedica.



PANEL

Investing in Commercial Stage Healthcare Companies

Allyson Rinderle, MBA

Principal, Private Equity, KKR

Allyson Rinderle (Menlo Park) joined KKR in 2017 and is a member of the Health Care industry team. She serves on the Board of Directors of Envision Healthcare and PetVet Care Centers and is a Board Observer of Impel NeuroPharma and Paige. Prior to joining KKR, Ms. Rinderle was a vice president at Longitude Capital, a health care venture growth firm. Previously, she was an analyst at Aisling Capital, a life science investment firm based in New York. Ms. Rinderle started her career as an analyst in J.P. Morgan's health care investment banking practice where she was involved in a number of mergers, acquisitions, and financing transactions. Ms. Rinderle received her B.S. in Biomedical Engineering with distinction from Yale University, graduating magna cum laude, Tau Beta Pi, and Phi Beta Kappa. She holds an M.B.A. from Stanford Graduate School of Business, where she was an Arjay Miller Scholar and received a Certificate in Public Management and Social Innovation.



PANEL

Investing in Commercial Stage Healthcare Companies

M. Craig Shepherd, LLB, MBA

Senior Managing Director, Blackstone

M. Craig Shepherd is a Senior Managing Director in the Blackstone Life Sciences group and a member of its Investment Committee. Since joining Blackstone in New York in 2017, Mr. Shepherd has played a leadership role in Blackstone's acquisition of Clarus in 2018 and Blackstone's \$2 billion investment with Alnylam Pharmaceuticals in 2020.

Prior to Blackstone, Mr. Shepherd was a Managing Director and a member of the Investment Committee at DRI Capital, a life sciences private equity firm dedicated to the acquisition of pharmaceutical royalties through its managed funds Drug Royalty I, II and III. He joined DRI from Amgen where he held roles in Amgen's global HQ in California and its international HQ in Switzerland.

Mr. Shepherd holds an MBA from Harvard Business School, a law degree from McGill University, and a BA from the University of Western Ontario. Mr. Shepherd is a member of the Healthcare Advisory Board of the Partnership Fund for New York City and a member of the McGill University Chancellor's Advisory Board.



PRESENTING COMPANIES

The Bloom Burton & Co. Healthcare Investor Conference hosts 66 of Canada's premier publicly traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry.

66

**Presenting
Companies**

23

**Private
Companies**

43

**Public
Companies**

Biotechnology

Medical Technology

Tools

Specialty Pharma

**Services /
Digital Health**

Tuesday, April 20, 2021 | 1:30 PM ET

AbCellera Biologics

● Public

(NASDAQ:ABCL)



AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 10:30 AM ET

AceAge

○ Private



AceAge, a healthcare technology company creating intuitive products to ease the aging process and improve health outcomes. AceAge's product, Karie, is a smart pill companion that organizes, schedules, and delivers pills, ideally suited for those needing to manage 3 or more medications simultaneously. Karie was designed to make medication management as simple as possible to ensure user independence and wellness, while providing caregivers with peace of mind. Please visit www.kariehealth.com for more information.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 11:30 AM ET

Aequus Pharmaceuticals

- Public

(TSXV:AQS)



Aequus Pharmaceuticals is a Canadian based specialty pharmaceutical company focusing on developing and commercializing high quality products in specialty therapeutic areas, particularly ophthalmology, critical care and transplant.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 1:30 PM ET

AlayaCare

○ Private



Founded in 2014, with offices in Canada, USA and Australia, AlayaCare is a cloud-based SaaS platform that offers clinical and operational tools for home and community care providers to improve efficiency and outcomes. AlayaCare offers a full suite of features to enhance the level of care delivered at home and through community providers including efficient scheduling, mobile storage of clinical documentation, real-time remote patient monitoring, virtual care functionality and many others.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 11:00 AM ET

Antibe Therapeutics

• Public

(TSX:ATE)



Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe's current pipeline includes three assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe's lead drug, otenaproxesul, is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. The Company's next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 10:00 AM ET

Appili Therapeutics

● Public

(TSX:APLI)



Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 2:30 PM ET

ARTMS

○ Private



ARTMS is the global leader addressing a growing unmet medical need for the production of high quality and high yield medical isotopes by commercializing ARTMS' proprietary solid targetry solution, the QUANTM Irradiation System, to cyclotron-equipped hospitals, clinics and radiopharmacies across the globe. ARTMS designs, develops, and manufactures all of the necessary cyclotron solid targetry hardware, consumables (targets, process materials and reagents), production know-how and regulatory approvals to allow our clients and our partner's cyclotron sites the ability for the local production of active pharmaceutical ingredients (APIs) such as Ga-68, Zr-89, Tc-99m and Cu-64. ARTMS performs additional value added services by working alongside innovators for the co-development of novel radiopharmaceuticals to demonstrate clinical utility and validation while moving the drug products from investigational to approval status with regulatory agencies such as Health Canada, FDA and EMA.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 2:30 PM ET

Aurinia Pharmaceuticals

● Public

(TSX:AUP, NASDAQ:AUPH)



Aurinia exists to make a difference. Our mission is to transform people's lives by delivering therapeutics that change the course of autoimmune disease. From the earliest days of the company, we've applied a creative, thoughtful and responsible approach to developing therapies for people in need. In addition to driving adoption of our approved therapy for appropriate people with lupus nephritis, we are also actively pursuing a broader portfolio of innovative drugs for autoimmune disease. Our strategy leverages the skills and knowledge of our incredible team and our deep experience in principled drug development and commercialization. Together, we are driven to make an impact for our patient communities as advocates and partners in innovation.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 3:00 PM ET

Avivagen

● Public

(TSXV:VIV)

Avivagen

Avivagen Inc. is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 2:00 PM ET

Bellus Health

● Public

(TSX:BLU, NASDAQ:BLU)



Bellus
HEALTH

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 11:00 AM ET

BioSyent

● Public

(TSXV:RX)



BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 3:00 PM ET

Canary Medical

○ Private



Canary Medical is a medical data company improving healthcare outcomes through the continuous collection, analysis, and monetization of data derived from proprietary, “smart” medical devices that self-report on function, diagnostic information, patient activity, side effects, and treatment failure for up to 20 Years.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 4:00 PM ET

CareRx

● Public

(TSX:CRRX)



CareRx is Canada's leading provider of specialty pharmacy services to seniors. We serve approximately 50,000 residents in over 900 seniors and other communities (long-term care homes, retirement homes, assisted living facilities, and group homes). At the core of our business is the care we have for the individuals and teams we serve and work with. We put care into every aspect of what we do.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 3:30 PM ET

Chinook Therapeutics

● Public

(NASDAQ:KDNV)



Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 3:00 PM ET

CloudMD Software & Services

● Public

(TSXV:DOC)



CloudMD

CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 7,000 psychiatrists, approximately 4,500 therapists and counsellors, approximately 4,000 psychologists, over 22,000 family physicians, over 34,000 medical specialists, over 1,500 allied health professionals, over 500 clinics, and 8 million patient charts across North America. CloudMD's Enterprise Health Solutions Division includes one of the top 4 Employee Assistance Programs in Canada and offers one comprehensive, digitally connected platform for corporations, insurers and advisors to better manage the health and wellness of their employees and customers.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 9:30 AM ET

Crescita Therapeutics

● Public

(TSX:CTX)

CR  SCITA
T H E R A P E U T I C S

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. In addition, we own multiple proprietary transdermal delivery platforms that support the development of patented formulations that facilitate the delivery of active ingredients into or through the skin.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 2:00 PM ET

Cybin

- Public

(NEO:CYBN)



Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 2:00 PM ET

Dialogue Health Technologies

● Public

(TSX:CARE)



Incorporated in 2016, Dialogue is Canada's premier virtual healthcare and wellness platform, providing affordable, on-demand access to quality care. Through our team of health professionals, we serve employers and organizations who have an interest in the health and well-being of their employees, members and their families. Our Integrated Health Platform™ is a one-stop healthcare hub that centralizes all of our programs in a single, user-friendly application, providing access to Services 24 hours per day, 365 days per year from the convenience of a smartphone, computer or tablet.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 11:30 AM ET

Dot Health

○ Private

dot health

Dot Health is a complete health data platform. We help patients, providers, and insurers securely and seamlessly request and access health records digitally via a Canada-wide network of over 30,000 health care service providers.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 3:30 PM ET

Domain Therapeutics

○ Private



Domain Therapeutics is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology. With teams at work in France and Canada, Domain operates multiple technologies aimed at validating G Protein-Coupled Receptors (GPCRs) mediating immunosuppression, at discovering first-in-class or best-in-class therapies, small molecules and antibodies, and at developing them in the clinic to create a pipeline of high-value proprietary programs.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 11:00 AM ET

ESSA Pharma

● Public

(NASDAQ:EPIX)

The logo for ESSA Pharma, featuring the letters 'ESSA' in a bold, blue, sans-serif font. The letter 'A' is stylized with a blue outline and a solid orange dot at its base.

ESSA is developing an investigational treatment for prostate cancer, EPI-7386, which blocks the N-terminal domain, located on the opposite end of the androgen receptor from the ligand-binding domain. Through this novel mechanism of action, ESSA is focused on providing a potential meaningful clinical benefit to patients with prostate cancer at all stages of the disease.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 4:00 PM ET

Eupraxia Pharmaceuticals

● Public

(TSX:EPRX)



Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

In addition to Eupraxia's lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 3:00 PM ET

FERO International

○ Private



Founded in 2020 and headquartered in Toronto, Ontario, Fero International is a global leader in specialized Med-Tech and large scale modular infrastructure. Fero provides innovative solutions to complex economic, social and defense needs for large governments, rural and urban communities and private companies across multiple industries.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 10:30 AM ET

Fibrocor Therapeutics

○ Private



Fibrocor is using its differentiated target identification and validation platform to discover precision medicines for fibrosis. Our first small molecule discovered using this platform is entering clinical trials in 2021, with a number of other molecules and fibrosis targets currently in various stages of development. The company has a broad strategic partnership with Galapagos NV (NASDAQ: GLPG), in addition to proprietary Fibrocor programs under development. Fibrocor is privately held, funded by strategic investors (Galapagos and Evotec) and a prominent European venture fund.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 1:30 PM ET

Field Trip Health

● Public

(CSE:FTRP)



field trip

Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 10:30 AM ET

Fusion Pharmaceuticals

● Public

(NASDAQ:FUSN)



Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 10:30 AM ET

Grey Wolf Animal Health

○ Private



Grey Wolf Animal Health, founded in 2015 by Dr. Ian Sandler, is a specialty animal health company focused on acquiring, licensing, marketing and commercializing products, solutions and services that meet the underserved needs of vets, pets and clinics in Canada. Grey Wolf currently has a diversified portfolio of products spanning pharmaceuticals, nutraceuticals and consumables, which are marketed to vet clinics coast to coast by our national sales team.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 2:30 PM ET

Hamilton Thorne

● Public

(TSXV:HTL)



Hamilton Thorne (www.hamiltonthorne.com) is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 10:30 AM ET

HLS Therapeutics

● Public

(TSX:HLS)



HLS Therapeutics Inc.

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 4:00 PM ET

IMV

- Public

(TSX:IMV, NASDAQ:IMV)



IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 10:00 AM ET

Intellijoint Surgical

○ Private



Intellijoint Surgical develops and commercializes surgical navigation solutions for total joint replacements. It is committed to improving patients' lives by providing every surgeon with effective, easy-to-use technology. Intellijoint HIP and Intellijoint KNEE smart navigation applications are both delivered through the Intellijoint Navigation System. It is a fast and easy-to-use, surgeon-controlled system that provides real-time measurements to optimize implant alignment and positioning during total hip and knee replacement surgery to help improve patient outcomes.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 4:00 PM ET

Inversago

○ Private



Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions including Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. Inversago is a private company currently funded by transatlantic investors in the life science sector.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 11:30 AM ET

Kardium

○ Private

The logo for Kardium features the word "Kardium" in a bold, red, sans-serif font. A thin grey line with a small pulse-like shape at its end is positioned above the letters "i" and "d". A registered trademark symbol (®) is located to the right of the line.

Kardium®

Kardium Inc. is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation (AF), which affects more than 37 million people worldwide. The Globe® Mapping and Ablation System is the most complete solution for AF, offering single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation – all in a single catheter. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has been recognized as a top company to work for in BC, including recognition as Medical Technology Company of the Year (2015) by LifeSciences BC.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 9:30 AM ET

Knight Therapeutics

● Public

(TSX:GUD)



Knight Therapeutics Inc. is a pan-American (ex-US) specialty pharmaceutical company focused on acquiring, in licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals in Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. Headquartered in Montreal, Knight has over 700 employees globally.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 2:30 PM ET

League

○ Private



Founded in 2014, League is a technology-focused health company powering the digital transformation of healthcare. Employers, pharmacy retailers, healthcare providers and payors use our award-winning platform to deliver integrated and personalized health experiences that drive consumer engagement. Hundreds of thousands of consumers across the US, Canada, the UK and Ireland use digital health platforms powered by League to access, navigate and pay for care.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 11:00 AM ET

Medexus Pharmaceuticals

● Public

(TSXV:MDP)



Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company's leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B - a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 3:30 PM ET

Medicago

○ Private

medicago

Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name - the Latin word for alfalfa, which was the first plant we worked with - embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth and global reach. We understand better than most that the path to success is not a straight line. As a pioneer of plant-based transient expression and manufacturing, Medicago has always sought a more effective way to improve human health. With nearly 20 years of experience and wisdom behind us, we are ready to disrupt the traditional approach to vaccines and therapeutics. Medicago has been privately held since 2013.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 10:00 AM ET

Medicenna Therapeutics

● Public

(TSX:MDNA, NASDAQ:MDNA)



Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 2:30 PM ET

Microbix Biosystems

● Public

(TSX:MBX)



Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health and wellbeing. We manufacture a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays and Quality Assessment and Proficiency (QAPs™) testing products. Microbix's business of producing high quality viral and bacterial preparations are the result of nearly three decades of experience in the field, including strain selection, reliable and efficient organism culture at scale, purification and methods of inactivation. As a result of Microbix's expertise, its products have received widespread and longstanding customer acceptance, with continuing growth in demand. Microbix's current catalogue of biological preparations covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases. The company also applies its biological expertise to develop other innovative and proprietary technologies and products. Its development project pipeline currently includes Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 11:30 AM ET

Mimi's Rock

● Public

(TSXV:MIMI)

MIMI'S  ROCK

Mimi's Rock Corp. is an online dietary supplement and wellness company which markets and sells its products under the Dr. Tobias, All Natural Advice and Maritime Naturals brand names. The Dr. Tobias brand features over 30 products, including the top-selling Colon 14-Day Cleanse and the #1 selling Omega 3 Fish Oil on Amazon.com. All Natural Advice and Maritime Naturals products focus on skin and beauty care. Products sold under the All Natural and Maritime Naturals brand names are made in Canada and registered with Health Canada and under the EU Cosmetics Act. All Natural Advice has been featured on BNN as a top selling skincare brand in Canada, and has been rated the #1 Beauty Brand on Amazon Canada for the past four years.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 2:30 PM ET

MindBeacon

● Public

(TSX:MBCN)



MindBeacon is developing a continuum of mental healthcare that includes self-guided psychoeducational and wellness content, Therapist Guided Programs and Live Therapy Sessions all offered virtually through their secure platform. As one of the first commercially available, digitally-native platforms to offer therapist-assisted internet-based Cognitive Behavioural Therapy in Canada, MindBeacon's professional service is designed around end users - their health, their way. Working with employers, insurance carriers and government ministries, MindBeacon's services are accessible, affordable and, most importantly, proven to be effective. MindBeacon is changing the therapy landscape by making professional care available to every Canadian, no matter when, where and how they choose to access it.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 10:00 AM ET

Miravo Healthcare

● Public

(TSX:MRV)



A Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology. Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and its manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 4:00 PM ET

NeuPath Health

● Public

(TSXV:NPTH)



NeuPath operates an end-to-end, integrated network of health care businesses focused on transforming the hope of a better life into the reality of a life more fully lived. NeuPath endeavors to achieve this goal by working with patients to return functionality lost due to chronic pain, spinal injuries, sports related injuries, and concussions. NeuPath's end-to-end solution is built on a base of research, with technology layered in, with a goal of better outcomes from assessments and treatments. The Company operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of health care providers.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 3:30 PM ET

Newtopia

● Public

(TSXV:NEWU)

newtopia

A tech-enabled habit change provider focused on preventing disease is launching the category of habit change provider to enable employees to live healthier every day. Through the company's long history of partnership and experience working with some of the world's largest employer and payer innovators, Newtopia identified both the need and solution for delivering workforce habit change at scale. In pioneering this new category, Newtopia created an individualized whole-person approach that prevents, reverses, and slows the progression of chronic disease while enriching mental health, resilience and human performance.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 2:00 PM ET

Nicoya Life Sciences

○ Private



Nicoya's mission is to accelerate the application of proteomics to advance human health. Our digital biosensor platform, Alto, enables rapid discovery, characterization and detection of biomarkers to bring the promise of precision health to the world.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 10:00 AM ET

Notch Therapeutics

○ Private



Notch is developing renewable, stem cell-derived immunotherapies, with an initial focus on cancer. We believe that cell therapies can bring value to patients and healthcare systems by being safe, effective, and accessible.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 9:30 AM ET

Oncolytics Biotech

● Public

(TSX:ONC, NASDAQ:ONCY)



Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 3:30 PM ET

OpSens

- Public

(TSX:OPS)



OpSens focuses mainly on coronary physiology products in interventional cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 4:00 PM ET

Perimeter Medical Imaging

● Public

(TSXV:PINK)



Perimeter Medical Imaging AI is an early-stage medical device company driven to transform cancer surgery with ultra high resolution and real time advanced imaging tools, addressing high areas of unmet medical need in cancer surgery workflows.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 11:00 AM ET

Precision Biomonitoring

○ Private



Precision
Biomonitoring

At Precision Biomonitoring we envision a world where we can instantly identify any organism on the spot, anywhere in the world. Founded in 2016, Precision Biomonitoring provides industry-leading expertise in molecular detection of organisms. Our very own TripleLock™ and Voilà!™ technologies aim to deliver on-site environmental, food, animal and human diagnostic testing solutions. We provide innovative molecular detection tools for various scenarios ranging from rapid, accurate, on-site human pathogens to any other organisms. Our relentless commitment to technological innovation and scientific excellence puts us at the forefront of technological innovations in the genomics industry.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 1:30 PM ET

Profound Medical

● Public

(TSX:PRN, NASDAQ:PROF)

PROFOUND

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO[®], a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO[®] is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. TULSA-PRO[®] has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO[®] is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.

Profound is also commercializing Sonalleve[®], an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 9:30 AM ET

Repare Therapeutics

● Public

(NASDAQ:RPTX)

RE **PARE**
THERAPEUTICS


Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx[®] platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Pol inhibitor program. For more information, please visit www.reparerx.com.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 11:30 AM ET

Satellos Bioscience

○ Private



Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in life threatening disorders. Our founding scientist, Dr. Michael Rudnicki discovered that the dysregulation of stem-cell polarity — a process that balances replenishment of stem cells and production of specialized tissue cells, including muscle — can lead to the inability of the body to properly repair and regenerate muscle throughout life.

Satellos is initially applying these discoveries to our lead program to develop a new therapeutic treatment which restores muscle regeneration in Duchenne muscular dystrophy, a lethal degenerative disease. Defects in muscle regeneration are also causative in many chronic conditions which we plan to pursue including sarcopenia (muscle wasting with age), cachexia (muscle wasting from chemotherapy or smoking) and various dystrophies. Founded in 2018, Satellos is headquartered in Canada.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 10:00 AM ET

Searchlight Pharma

○ Private



Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in-class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women's health, urogynecology, and urology, our team is committed to improving people's lives by bringing the right products to market. Follow us, learn more about what we do, and get to know our product portfolio at www.searchlightpharma.com.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 3:30 PM ET

Skylight Health Group

● Public

(TSXV:SHG)



Skylight Health Group is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multidisciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations. With a patient roster of over 155,000 patients, the Company's operations servicing 16 states and continues to expand in services and locations both organically and by way of strategic acquisitions. The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost. For more information, visit www.skylighthealthgroup.com.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 9:30 AM ET

Synaptive Medical

○ Private

Synaptive

Privately funded and based in Toronto, Synaptive Medical Inc., a medical device and technology company, develops and supports surgical technologies and therapies. The team at Synaptive consists of visionaries and thought leaders in surgical planning and navigation, robotic digital microscopy, Magnetic Resonance Imaging (MRI) and data platforms. With our family of connected surgical devices, doctors are seeing the brain and body in ways they never have before. By taking an innovative, critical and holistic approach to identifying the connections between all aspects of clinical procedures, we offer fully-integrated solutions in and beyond the operating room that help doctors and researchers achieve better outcomes for their patients. In collaboration with leading clinicians and healthcare systems, Synaptive is revolutionizing products and services that cross traditional barriers to enable continuous improvement in care delivery, in and beyond the operating room.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 10:30 AM ET

Theratechnologies

● Public

(TSX:TH, NASDAQ:THTX)



Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently have commercial medicines for the treatment of HIV-1 and HIV-associated lipodystrophy and a robust research pipeline focused on the development of novel therapies for oncology, hepatology and HIV.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 3:00 PM ET

Think Research

● Public

(TSXV:THNK)



We're organizing the world's health knowledge so that everyone gets the best care. Our knowledge-based tools empower healthcare providers at the point of care and beyond. We work across all sectors, including acute, primary, and long-term care. Our healthcare technology solutions support the clinical decision making process, standardize care, and improve patient outcomes. You can find our products and services in over 2,800 facilities across Canada, the US, and EU, with millions of patients impacted every year.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 2:00 PM ET

Titan Medical

● Public

(TSX:TMD, NASDAQ:TMDI)

TITAN MEDICAL

Titan Medical is focused on developing robotic assisted technologies for application in single access surgery. We are developing our Enos™ system to become the new standard of care in robotic single access surgery, with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. Our goals are to enable better patient outcomes by allowing faster recovery times and less trauma and scarring, and improved clinical performance, operating room efficiency and favorable hospital economics.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 9:30 AM ET

Triumvira Immunologics

○ Private



Triumvira Immunologics Inc. (“Triumvira”) is a clinical stage immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. Our TAC platform offers competitive advantages over CAR-T and TCR therapies, including: Co-opting the natural T cell signaling pathways; Design of a safer and more effective T cell therapy; Demonstration of superiority in preclinical models; A strong intellectual property platform including composition of matter applications, and freedom to operate; An expanding pipeline including solid and liquid tumor indications. Triumvira’s lead product, TAC01-HER2 will enter the clinic in May 2021 for the treatment of HER2-overexpressing solid tumors.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 2:00 PM ET

Viemed

- Public

(TSX:VMD, NASDAQ:VMD)



BEST IN CLASS HOME RESPIRATORY CARE

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 1:30 PM ET

Virica Biotech

○ Private



Virica Biotech's pioneering and proprietary Viral Sensitizers (VSE™) improve virus production processes to deliver higher yields at lower cost, and bolster viral medicines from vaccines to gene therapies. Virica deploys its collection of proprietary VSE small molecules by developing custom VSE formulations for specific viral platforms that are either Client Driven or that rely on Virica's Formulation Services and know-how in high-throughput virology. VSEs are simple additives in the early steps of manufacturing and not present in the final product. They are small molecules amenable to GMP manufacturing, complete with analytical assays and toxicological information to support regulatory requirements. Virica's business model is based on low barrier to entry and broad applicability, leading to a portfolio of long-term VSE supply agreements that scale as our clients succeed through their product development objectives.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 1:30 PM ET

WELL Health Technologies

● Public

(TSX:WELL)



WELL Health

WELL is an omni-channel digital health company whose overarching objective is to empower doctors to provide the best and most advanced care possible while leveraging the latest trends in digital health. As such, WELL owns and operates 27 primary healthcare clinics, is Canada's third largest digital Electronic Medical Records (EMR) supplier serving over 2,200 medical clinics, operates a leading national telehealth service in Canada and the United States, and is a provider of digital health, billing and cybersecurity related technology solutions. WELL is an acquisitive company that follows a disciplined and accretive capital allocation strategy. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL". To access the Company's telehealth service, visit: tiahealth.com and for corporate information, visit: www.WELL.company.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 3:00 PM ET

Xenon Pharmaceuticals

● Public

(NASDAQ:XENE)



We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

PRESENTING COMPANIES

Wednesday, April 21, 2021 | 11:00 AM ET

Zucara Therapeutics

○ Private



Zucara Therapeutics Inc. is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin dependent diabetes. ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. Zucara has recently raised US\$21M in a Series A financing that provides capital to conduct Phase 1 and 2 clinical trials. Phase 1 trials are underway with results expected in 2021.

PRESENTING COMPANIES

Tuesday, April 20, 2021 | 11:30 AM ET

Zymeworks

● Public

(NYSE:ZYME)



Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

PRESENTING COMPANIES

SPONSORS



**Baker
McKenzie.**



Blakes



**mccarthy
tetraault**



BLOOM BURTON & CO.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade.

We speak with large companies and investors every day and we know what they are looking for. We are therefore the ideal group to help our companies plan their capital market strategies, investigate the relevance of new biological pathways, consider new therapeutic indications and clinical designs, and catalogue and diligence new products or companies for acquisition.



We identify the most impactful companies for our investor network and we provide tailor-made support solutions for the management teams and boards of healthcare.

SERVICES

Our services help identify, cultivate and create investment opportunities in the healthcare sector on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our seven business services work cohesively to accelerate monetization for both company and investor clients.

**Raising Capital
& Financing**

Sourcing capital to fund healthcare opportunities

**M&A
Advisory**

Enabling monetization through strategic transactions

**Equity
Research**

Influential opinions and insights on companies

**Sales &
Trading**

Generating returns for investors

**Monetization
Planning**

Helping realize the value of innovations

**Direct
Investment**

Maximizing opportunities in healthcare investing

**Company
Creation**

Establishing new opportunities in healthcare

**At Bloom Burton & Co.
we serve investors and
companies seeking to
make meaningful change
to the healthcare industry.**

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

OUR METHODOLOGY

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster.

Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a wider range of investment options, greater understanding of crossborder rules, relationships with international investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

We never blame “market conditions” or approach transactions as a “numbers game”.

Our long-term commitment to each investor and company challenges us to continuously refine our strategies until we achieve success. We are creative in our approach to financing and growth, and tenacious in finding the right transaction for all parties.

LOGISTICS

Keynote Speaker

Scott Gottlieb, M.D., 23rd Commissioner of the U.S. FDA

Panel Discussions

Investing in R&D Stage Healthcare Companies

Investing in Commercial Stage Healthcare Companies

1-on-1 Meetings

Professional investors will have the opportunity to request 1-on-1 meetings with private and public presenting companies

Company Presentations

66 of Canada's premier publicly-traded and venture-backed private healthcare companies

A photograph of a man in a dark suit and glasses smiling at a dinner table. He is looking towards the left. In the background, there are several tall floral centerpieces with white flowers and green leaves. The scene is dimly lit, suggesting an evening event.

2021
BLOOM BURTON
AWARD GALA

September 30, 2021



bloom burton & co

/accelerating returns in healthcare[®]